熱門資訊> 正文

Praxis认为脑病资产瑞卢三嗪行动日期延长

2026-06-30 06:14

Praxis Precision Medicines(PRAX) 0
高盛(GS) 0

The US FDA has extended the review period for Praxis Precision Medicines' (PRAX) application for relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies by three months to Dec. 27.
The reason is that the company submitted additional sensitivity analyses of existing data, which the agency considers a "major amendment."
No new studies are requested, and no safety or manufacturing issues were mentioned.

More on Praxis Precision Medicines

Praxis 'Strong Buy': PDUFA In Early 2027 For Ulixacaltamide And BTD Elsunersen
Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor
Praxis gains FDA Breakthrough Therapy Status for elsunersen for encephalopathy
Praxis a new outperform at RBC on recent pullback

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。